Green Plains Partners (NASDAQ:GPP) reported quarterly earnings of $0.44 per share. This is unchanged from the same period last year.
Moleculin Presents Preliminary Efficacy Findings From Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles Of Annamycin For The Treatment Of Soft Tissue Sarcomas Lung Metastases
– Poster Presented at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting– Annamycin continues to be 100% non-cardiotoxic– Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the
